Anti-CD55 / DAF Antibody

1/2
Price:
Size:
Number:

Anti-CD55 / DAF Antibody (Rabbit Monoclonal antibody) General Information

Product name
Anti-CD55 / DAF Antibody
Validated applications
ELISA,ELISA(Cap),FCM,ICC/IF,IF
Species reactivity
Reacts with: Human
Specificity
Human CD55 / DAF
No cross-reactivity in ELISA with
Human CD97
Immunogen
Recombinant Human CD55 protein (Catalog#10101-H08H)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human CD55 / DAF (rh CD55; Catalog#10101-H08H; NP_000565.1; Met 1-Ser 353).
Source
Monoclonal Rabbit IgG Clone #028
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-CD55 / DAF Antibody (Rabbit Monoclonal antibody) Validated Applications

Application Dilution
ELISA 1:5000-1:10000
ICC-IF 1:20-1:100
FCM 1:25-1:100
ELISA(Cap) 1:250-1:2000
Notes
ELISA(Cap): This antibody will detect Human CD55 / DAF in ELISA pair set (Catalog: # SEK10101). In a sandwich ELISA, it can be used as capture antibody when paired with (Catalog: # 10101-MM03).
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-CD55 / DAF Antibody (Rabbit Monoclonal antibody) Images

Flow cytometric analysis of human CD55 expression on K562 cells. Cells were stained with purified anti-Human CD55, then a FITC-conjugated second step antibody. The histogram were derived from events with the forward and side light-scatter characteristics of intact cells.
Immunofluorescence staining of Human CD55 in JURKAT cells. Cells were fixed with 4% PFA, blocked with 10% serum, and incubated with Rabbit anti-Human CD55 monoclonal antibody (1:60) at 37℃ 1 hour. Then cells were stained with the Alexa Fluor® 488-conjugated Goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue). Positive staining was localized to plasma membrane.

Anti-CD55 / DAF Antibody: Alternative Names

Anti-CR Antibody; Anti-CROM Antibody; Anti-DAF Antibody; Anti-TC Antibody

CD55 / DAF Background Information

CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 3 SCRs (short consensus repeats) in their plasma-exposed regions. It is a major regulator of the alternative and classical pathways of complement activation and is expressed on all serum-exposed cells. CD55 is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. DAF seems to exert different functions beyond its immunological role such as promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility. It is commonly hijacked by invading pathogens, including many enteroviruses and uropathogenic Escherichia coli, to promote cellular attachment prior to infection. This 7-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It inhibits complement activation by suppressing the function of C3/C5 convertases, thereby limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology.
Full Name
CD55 molecule, decay accelerating factor for complement (Cromer blood group)
References
  • Lea S. (2002) Interactions of CD55 with non-complement ligands. Biochem Soc Trans. 30(Pt 6): 1014-9.
  • Mikesch JH, et al. (2006) The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 28(5-6): 223-32.
  • Wang Y, et al. (2010) Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. J Neuroinflammation. 7:24.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait